Barrington Research Lowers Haemonetics (NYSE:HAE) Price Target to $89.00

Haemonetics (NYSE:HAE) had its target price lowered by analysts at Barrington Research from $94.00 to $89.00 in a research report issued on Tuesday. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s target price would suggest a potential upside of 70.09% from the company’s previous close.

A number of other equities analysts have also weighed in on HAE. Wall Street Zen lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday. Citigroup restated an “outperform” rating on shares of Haemonetics in a research report on Tuesday. Mizuho lowered their price target on shares of Haemonetics from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. BTIG Research reiterated a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a report on Friday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $79.33.

Haemonetics Stock Performance

HAE opened at $52.32 on Tuesday. The firm has a market capitalization of $2.43 billion, a PE ratio of 25.90, a PEG ratio of 1.10 and a beta of 0.53. Haemonetics has a twelve month low of $47.31 and a twelve month high of $87.32. The firm’s 50-day moving average price is $59.19 and its 200 day moving average price is $66.71. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. Haemonetics’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, sell-side analysts expect that Haemonetics will post 5.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kemnay Advisory Services Inc. purchased a new stake in shares of Haemonetics in the 4th quarter valued at approximately $26,000. True Wealth Design LLC raised its stake in shares of Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 335 shares during the period. Leonteq Securities AG purchased a new stake in shares of Haemonetics in the 4th quarter valued at approximately $30,000. EverSource Wealth Advisors LLC raised its stake in shares of Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the period. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Haemonetics in the 4th quarter valued at approximately $34,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.